Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

NCT01620463 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and effects of the drug liraglutide in healthy Japanese adults to understand how it is processed in the body and its impact on weight.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 32 people

Who can join Ages 20–45 · male only Healthy volunteers accepted.

Timeline Started 2002-12 · est. completion 2003-03

Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT01620463 ↗

Description as written by the study sponsor.

This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of NNC 90-1170 (liraglutide) in healthy Japanese male subjects.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
placebo Drug

Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group

Main thing measured	Body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01620463 ↗